R. B. Pearson

Nuclear stabilisation of p53 requires a functional nucleolar surveillance pathway

This study identifies the nucleolar surveillance pathway (NSP) as a central regulator of p53 stability, showing its role in integrating various cellular stresses and its potential as a therapeutic target in cancer.

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.

Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer

This study identifies that combining RNA Polymerase I inhibitor CX-5461 with TOP1 inhibitor topotecan enhances DNA damage response and efficacy in high-grade serous ovarian cancer.

RNA binding kinase UHMK1 regulates therapy induced metabolic adaptation in BRAFV600 melanoma

The paper identifies UHMK1 as a regulator of metabolic adaptation in BRAFV600 melanoma under targeted therapy, showing its role in mRNA transport and translation and its impact on therapy resistance.

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

This study shows CX-5461, an RNA polymerase I inhibitor, enhances PARP inhibitor efficacy in HR-deficient HGSOC by inducing replication stress and DNA damage, overcoming resistance mechanisms.

Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer

The paper identifies somatic mutations in early metazoan genes that disrupt regulatory links between unicellular and multicellular genes in cancer, linking these mutations to drug response.